Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 3Recruiting 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 107Head & Neck 68Thoracic 49Genitourinary 24Breast 24Gynecologic 15Other solid neoplasm 13Dermatologic 11Lymphoid 5Tumor-Agnostic 4Sarcoma 4Other neoplasm 2CNS 2Endocrine 1

Conditions

Lymphoma 2Pyloric Stenosis, Hypertrophic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Hodgkin Disease 1

Interventions

Cyclophosphamide 886Rituximab 864Vincristine 382Etoposide 381fludarabine 342Cytarabine 341Doxorubicin 340fludarabine phosphate 319Methotrexate 310Dexamethasone 283Prednisone 282Lenalidomide 245Filgrastim 228Melphalan 200Peripheral Blood Stem Cell Transplantation 184Radiotherapy 175Whole-Body Irradiation 172Busulfan 165Mycophenolic Acid 161venetoclax 158Bendamustine Hydrochloride 158Granulocyte Colony-Stimulating Factor 151Tacrolimus 145ibrutinib 144Bortezomib 138obinutuzumab 125Gemcitabine 113Cyclosporine 110Antilymphocyte Serum 103Carmustine 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × toripalimab × Lymphoid × Clear all
NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Recruiting
185 enrolled
Lymphoid

Hodgkin Disease

NCT04058470 2022-04-14

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Sun Yat-sen University

Phase 1/2 Unknown
140 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT03316144 2020-09-30

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Completed
13 enrolled
Lymphoid

Lymphoma

NCT04338282 2020-04-08

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Beijing Tongren Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT02836834 2019-10-22

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Unknown
33 enrolled
LymphoidThoracic

Lung Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡